Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-T cells (Minsk Scientific-Practical Center)
- Development stage
- Unknown
- Lead developer
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This autologous chimeric antigen receptor (CAR) T-cell therapy is designed to target B-cell maturation antigen (BCMA), a protein predominantly expressed on the surface of malignant plasma cells. Developed and manufactured by the Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology in Belarus, the therapy involves harvesting a patient's T cells, genetically modifying them to express a BCMA-specific CAR, and re-infusing them following lymphodepleting chemotherapy with cyclophosphamide and fludarabine. It is primarily indicated for the treatment of relapsed or refractory multiple myeloma, aiming to induce deep and durable remissions by leveraging the patient's own immune system to selectively eliminate cancerous cells. The therapy is currently being evaluated in Phase I/II clinical trials to determine its safety profile and clinical efficacy in adult populations.
- Other names
- anti-BCMA CAR-T cellsBCMA-targeted CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-T cells (Minsk Scientific-Practical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-T cells (Minsk Scientific-Practical Center).